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Abstract
Lynch syndrome (LS) is caused by mutations in mismatch repair genes and is characterized by a high cumulative risk for the develop-
ment of mainly colorectal carcinoma and endometrial carcinoma. Early detection of LS is important since surveillance can reduce mor-
bidity and mortality. However, the diagnosis of LS is complicated by the absence of a pre-morbid phenotype and germline mutation
analysis is expensive and time consuming. Therefore it is standard practice to precede germline mutation analysis by a molecular diag-
nostic work-up of tumours, guided by clinical and pathological criteria, to select patients for germline mutation analysis. In this review
we address these molecular analyses, the central role for the pathologist in the selection of patients for germline diagnostics of LS, as
well as the molecular basis of LS.
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Lynch syndrome
Colorectal cancer (CRC) is the most common malignancy within the
European Union and ranks second to lung cancer as a cause of can-
cer-related mortality [1]. CRC results from both genetic and environ-
mental factors. The most common genetic susceptibility for CRC is
Lynch syndrome (LS), formerly known as hereditary non-polyposis
colorectal cancer (HNPCC). LS accounts for approximately 3% of all
CRCs [2, 3], and also for 2% of all endometrial cancers [4]. The bur-
den of LS is considerably greater than these percentages imply, as
the cancers are diagnosed at a young age and synchronous or
metachronous malignancies occur in 30% of the patients [5, 6].
LS is characterized by a high lifetime risk for the development
of CRC (20–70%), endometrial cancer (15–70%) and other extra-
colonic cancers (15%) [7–14]. These extra-colonic malignan-
cies include carcinomas of the small intestine, stomach, pancreas
and biliary tract, ovarium, brain, upper urinary tract and skin. LS
is caused by germline mutations in mismatch repair (MMR) genes
[15], and the definitive diagnosis is currently made by identifica-
tion of an inactivating germline mutation in one of the MMR genes
MLH1, MSH2, MSH6 or PMS2 [16]. Early detection of LS is of
great importance, particularly in pre-symptomatic mutation carriers,
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since colonoscopic surveillance has proven to reduce CRC mor-
bidity and mortality by 65–70% [17–19] and prophylactic surgery
may prevent endometrial and ovarium carcinoma effectively [20].
Individuals with a predisposing mutation are candidates for partic-
ipation in surveillance programs.
The diagnosis of LS is hampered by the absence of specific
diagnostic features and the first manifestation in many patients is
the presence of an advanced cancer. Furthermore, DNA mutation
analysis is time consuming and expensive. For these reasons,
DNA analysis is generally preceded by a molecular diagnostic
work-up to select patients as candidates for genetic tests. This
molecular diagnostic work-up may be guided by several clinical
and pathological criteria such as the presence of LS associated
malignancies, number of malignancies and age at cancer diagno-
sis, family history as well as histological tumour features such as
mucinous or signet-ring differentiation. In this review, we address
the central role for the pathologist in the selection of patients for
germline diagnostics of LS, the molecular analyses to identify LS
as well as the molecular basis of LS.
Identification of patients at risk 
for Lynch syndrome
Different models and strategies have been developed to identify
patients with LS. In 1990, the Amsterdam Criteria I were devel-
oped to provide a basis for uniformity in collaborative studies to
find the disease-causing gene (Table 1) [21]. These criteria were
designed to be highly specific at the expense of the sensitivity 
[3, 22]. They were criticized because extra-colonic tumours were
not taken into account, thereby excluding classical LS families.
Therefore, the Amsterdam Criteria II were established in 1999
(Table 2) [23]. However, many families with the syndrome (i.e.
mutation carriers) do not meet these criteria [24], usually because
these families are too small or there is a late onset of the disease.
In addition, obtaining a thorough family history is difficult in clin-
ical practice [25] and patients may have limited knowledge of their
family history [26, 27].
In 1997, the Bethesda Guidelines were published to select
patients whose tumours should be analysed for molecular fea-
tures associated with LS, i.e. microsatellite instability (MSI), to
identify potential mutation carriers (Table 3) [28]. The Bethesda
Guidelines have been revised in 2004 to make them more suitable
for use in clinical practice, and are not only based on family his-
tory, but also on age at cancer diagnosis, number of LS-associ-
ated carcinomas and certain histological tumour features (Table 4)
[29]. These histological tumour features, associated with LS,
include the presence of tumour-infiltrating lymphocytes, a
Crohn’s-like lymphocytic reaction, mucinous or signet-ring cell
differentiation and a medullary or undifferentiated and solid
growth pattern. The additional value of these pathology charac-
teristics in the selection of tumours for further testing for LS has
been described previously [30, 31]. However, these histological
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Table 1 Amsterdam criteria I [21]
Table 3 Original Bethesda Guidelines [28]
Table 2 Amsterdam criteria II [23]
Families must fulfil all criteria:
1. There should be at least three relatives with a CRC.
2. One should be a first-degree relative of the other two.
3. At least two successive generations should be affected.
4. At least one should be diagnosed before the age of 50 years.
5. Familial adenomatous polyposis (FAP) should be excluded.
6. Tumours should be verified by pathological examination.
Families must fulfil all criteria:
1. There should be at least three relatives with a LS-associated cancer*.
2. One should be a first-degree relative of the other two.
3. At least two successive generations should be affected.
4. At least one should be diagnosed before the age of 50 years.
5. Familial adenomatous polyposis (FAP) should be excluded in the
CRC case(s), if any.
6. Tumours should be verified by pathological examination.
*CRC, cancer of the endometrium, small bowel, ureter or renal pelvis.
Individuals meeting any one of the following should undergo MSI testing:
1. Individuals with cancer in families that meet the Amsterdam criteria.
2. Individuals with two LS-related cancers, including synchronous
and metachronous CRCs or associated extracolonic cancers*.
3. Individuals with CRC and a first-degree relative with CRC and/or
LS-related extracolonic cancer and/or a colorectal adenoma; one of
the cancers diagnosed at age 45 years, and the adenoma diag-
nosed at age 40 years.
4. Individuals with CRC or endometrial cancer diagnosed at 
age 45 years.
5. Individuals with right-sided CRC with an undifferentiated pattern
(solid/cribriform) on histopathology diagnosed at age 45 years ‡.
6. Individuals with signet-ring-cell-type CRC (more than 50% signet
ring cells) diagnosed at age 45 years.
7. Individuals with adenomas diagnosed at age 40 years.
*Endometrial, ovarian, gastric, hepatobiliary or small-bowel cancer or
transitional cell carcinoma of the renal pelvis or ureter.
‡Solid/cribriform defined as poorly differentiated or undifferentiated
carcinoma composed of irregular, solid sheets of large eosinophilic
cells and containing small gland-like spaces.
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features are related to both microsatellite unstable sporadic
tumours as well as LS tumours. Therefore the ability to identify
LS patients alone on the basis of these tumour features is limited
[32]. In addition, the assessment of these histological tumour
features indicating MSI is poorly implemented in daily clinical
practice [32].
At present, the most widely accepted recommendation for the
identification of patients with LS is based on the combination of
these revised Bethesda Guidelines and MSI testing. This combi-
nation has proven to be an effective and efficient strategy for LS
identification, with a sensitivity for detection of mutation carriers
reported from 72% [3] up to 100% [33–36], and a specificity
ranging from 77% to 98% [33, 35, 36]. However, these criteria
have been criticized because of the use of broad and complex
variables, and families with MSH6 and possibly also PMS2 muta-
tions remain undetected [37]. It has also been shown in several
studies that these criteria are poorly implemented in clinical prac-
tice [32, 38–40].
In 2005, a Dutch group therefore developed a new strategy for
the detection of LS [41]. In this strategy the pathologist selects
newly diagnosed patients fulfilling one of the following criteria for
MSI analysis; (1) CRC before the age of 50 years, (2) Two LS-
associated tumours, including synchronous or metachronous
CRCs or LS-associated tumours or (3) adenoma before the age of
40 years. These criteria, known as MIPA criteria, simplify the
Bethesda guidelines in such a way that pathologists, without
knowledge of family history, can easily apply them. These criteria
were found to be effective, efficient and feasible in daily practice
[41, 42].
In The Netherlands, the diagnosis of LS is currently based on
a nationwide guideline for MSI analysis (Table 5), that was intro-
duced in January 2008 (www.oncoline.nl). This guideline resem-
bles the MIPA criteria. MSI analysis (and immunohistochemistry
of the MMR proteins) is requested by the pathologist in patients
newly diagnosed with CRC or endometrial carcinoma before the
age of 50 years, or patients with two LS-associated tumours
(including synchronous and metachronous CRCs or LS-associ-
ated tumours) before the age of 70 years. Presence of multiple LS-
associated cancers is registered in PALGA, the nationwide network
and registry of histopathology and cytopathology in The
Netherlands (www.palga.nl). For MSI analysis based on a positive
family history, referral to a clinical geneticist is indicated. In those
cases MSI analysis will generally be performed when the (revised)
Bethesda or Amsterdam Criteria are met and if archival paraffin-
embedded tumour tissue can be obtained.
Since clinical criteria do not quantify the likelihood of being a
mutation carrier, refined algorithms and multivariable models have
been developed to make a quantitative estimation of the risk of
carrying a germline MMR-gene mutation, without the requirement
of tissue [36]. Several models that combine personal and familial
data have been developed, such as the Leiden model, the
Edinburgh Model, Premm1,2 and the MMR-pro model [43–46].
One of the advantages of the quantitative models is that the
threshold for sensitivity or specificity of the model can be adjusted
based upon the clinical situation. However, the role for these mod-
els in daily clinical practice remains to be determined.
At present a study (called LIMO and coordinated by the
Erasmus MC, Rotterdam, The Netherlands) is performed to deter-
mine whether further improvement of LS diagnostics can be
obtained by the performance of MSI analysis in CRC patients up
to the age of 70 years. MSI analysis is performed in a prospective
consecutive series of 1000 newly diagnosed CRC patients 
70 years, and the results are expected in 2010.
Molecular basis of Lynch syndrome
and sporadic MMR-deficient tumours
LS is caused by a germline mutation in one of the MMR genes,
most commonly MLH1 and MSH2 (90%) [47, 48], but also
MSH6 and PMS2 [37, 49, 50]. LS patients are born with a
germline mutation in one of these MMR genes, and acquire inac-
tivation of the second wild-type allele in their tumours, fulfilling
Knudson’s two hit hypothesis for inactivation of tumour suppres-
sor genes [51]. Because of the high chance of inactivation of the
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Table 4 Revised Bethesda Guidelines [29]
Table 5 Dutch guideline for MSI testing (www.oncoline.nl)
Individuals meeting any one of the following should undergo MSI testing:
1. CRC diagnosed in an individual under age 50 years.
2. Presence of synchronous, metachronous colorectal, or other 
LS-associated tumours*, regardless of age.
3. CRC with the MSI-H histology‡, in a patient 60 years of age.
4. CRC in 1 or more first-degree relatives with a LS-related tumour*,
with 1 of the cancers being diagnosed under age 50 years.
5. CRC diagnosed in 2 or more first- or second-degree relatives with
LS-related tumours*, regardless of age.
*Endometrial, ovarian, gastric, small bowel, pancreas, hepatobiliary
tract, renal pelvis or ureter, and brain tumours, sebaceous gland
 adenomas and keratoacanthomas.
‡Presence of tumour-infiltrating lymphocytes, Crohn’s like lymphocytic
reaction, mucinous or signet-ring differentiation, or medullary growth
pattern.
The pathologist is advised to requests MSI testing (and immunohis-
tochemistry of the MMR proteins) in the following patients:
1. CRC or endometrial carcinoma before the age of 50 years. 
2. A second CRC before the age of 70 years.
3. CRC before the age of 70 years AND another synchronous or
 previous LS-associated tumour*.
*CRC, endometrial, ovarian, gastric, small bowel, pancreas, hepatobil-
iary tract, renal pelvis or ureter, and brain tumours, sebaceous gland
adenomas and keratoacanthomas.
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homologous wild-type allele during life, LS transmits phenotypi-
cally in an autosomal dominant fashion. The somatic inactivation
of the corresponding wild-type allele occurs almost exclusively by
small mutations or (partial) gene loss, and bi-allelic inactivation
then leads to complete abolition of the protein function. This
results in a defective DNA MMR system, since the protein prod-
ucts of the MMR genes are involved in correction of nucleotide
base mismatches and small insertions or deletions that arise dur-
ing DNA replication [52–54].
The mechanism of MMR has been largely elucidated (Fig. 1).
MSH2 (mutS homologue 2) forms a heterodimer with MSH6
(mutS homologue 6), sliding along the DNA as a clamp to identify
single nucleotide mispairs and small insertions and deletions [55,
56]. MLH1 (mutL homologue 1) dimerizes with PMS2 (post-mei-
otic segregation 2) and binds to the MSH2-MSH6 complex.
Together this group of four proteins recruits an exonuclease to
perform the DNA repair [57, 58]. If any of the four major proteins
(MSH2, MLH1, MSH6, or PMS2) is functionally inactive, mis-
matches are not repaired. A defective DNA MMR system increases
the mutation rate and makes the cell vulnerable to mutations in
genes controlling cell growth (including tumour suppressor genes
and oncogenes), resulting in an elevated cancer risk.
In case of a defective MMR system, mutations occur frequently
in small (usually mononucleotide or dinucleotide) repetitive DNA
sequences, known as microsatellites [59, 60]. In MMR deficient
tumour cells the number of nucleotide repeat units of microsatel-
lites can deviate from the corresponding normal DNA; the number
of repeats is usually decreased, but occasionally increased (Fig. 2).
This variation in repeat units and thus length or size of microsatel-
lites is called MSI. MSI (formerly referred to as MIN, another
abbreviation for MSI, or replication error abbreviated as RER) 
is the molecular hallmark of LS since approximately 95% of all 
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Fig. 1 The MMR system. During
DNA replication, insertions or dele-
tions of one or more nucleotides
and single nucleotide mismatches
may occur. For example: (A) A sin-
gle nucleotide mismatch occurs
(GT in red). (B) MSH2 and MSH6
form a heterodimer and recognize
the mismatch. (C) MLH1 and PMS2
dimerize and bind to the MSH2-
MSH6 complex. (D) The complex of
four proteins activates an exonucle-
ase to perform the DNA repair.
Fig. 2 MSI. A schematic microsatel-
lite is indicated (poly A track). When
the tumour cells have an intact
MMR system the size of the
microsatellite will be the same in
DNA isolated from normal (N) and
from tumour (T) cells: microsatellite
stable (MSS) tumour. In case of a
defect in MMR the size of the
microsatellite (number of repeat
units) can change (in most cases
becomes shorter) when comparing
N with T DNA: microsatellite unsta-
ble (MSI) tumour. Asterisks indicate
the microsatellite unstable tumour
DNA fragment.
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LS-associated cancers show MSI [61–63]. MSI thereby serves as
a reliable phenotypic marker of MMR deficiency which is easy to
evaluate in order to pre-select patients for germline mutation
analysis of the MMR genes.
Despite the fact that tumour MSI is a reliable marker for MMR
deficiency, it is a marker for LS with limited specificity since 15%
of sporadic CRCs also demonstrate a MSI phenotype. This is
mainly caused by somatic hypermethylation of the MLH1-gene
promoter [64, 65]. DNA methylation is an epigenetic DNA modifi-
cation that specifically targets cytosine residue at CpG dinu-
cleotides. Genomic regions that contain a high frequency of CpG
dinucleotides are called CpG islands, present in the promoters of
about 40% of all human genes, including the MLH1-gene [66].
Hypermethylation of CpG islands in the MLH1 promoter causes
severe inhibition of gene transcription thereby functionally mim-
icking an inactivating gene mutation. If both copies of the gene are
inactivated (mainly by bi-allelic hypermethylation), the DNA MMR
function of MLH1 is lost. This leads to microsatellite unstable can-
cers, especially in older patients [65]. MLH1 deficient microsatel-
lite unstable tumours can be assessed for MLH1 hypermethylation
to distinguish sporadic CRCs from LS-related cancers.
Theoretically, sporadic hypermethylation of the other MMR genes
is possible but has not yet been demonstrated.
Specific activating mutations in the BRAF oncogene, usually
V600E missense mutations (formerly reported as V599E), can be
detected in 40–87% of all sporadic microsatellite unstable
tumours. An oncogenic BRAF mutation has been described only
once [67] in numerous investigated LS tumours [68–75, 76].
These results indicate that BRAF mutations are closely correlated
with MLH1 methylation in sporadic CRCs [69–72, 76, 77].
Therefore, BRAF mutation status can be used to identify sporadic
microsatellite unstable tumours, although it has been demon-
strated that determination of hypermethylation of the MLH1 gene
promoter is more sensitive to detect sporadic MSI tumours [69].
In addition to sporadic forms of MLH1 promoter hypermethy-
lation, germline epimutations of MLH1 (soma-wide mono-allelic
hypermethylation of the gene promoter) have also been reported
[78–85]. Germline MLH1 hypermethylation, often showing some
degree of mosaicism, is functionally equivalent to an inactivating
mutation and produces a clinical phenotype that resembles LS.
Inheritance of epimutations is weak as the methylation can be
cleared on passage through the germline (germline MLH1 pro-
moter epimutations are reversible during meiosis) and so can
display non-Mendelian inheritance. Heritability of epimutations
might also be explained by the inheritance of an unknown predis-
position to epimutations, rather than the inheritance of the
epimutation itself [86]. Although very rare, germline MLH1 pro-
moter methylation should be considered in younger individuals or
individuals with multiple LS-associated tumours without a family
history who present with an MSI tumour showing loss of MLH1
expression [81, 82].
Besides germline MLH1 hypermethylation, a new mechanism
of germline MSH2 hypermethylation has recently been discovered
[87]. Ligtenberg et al. showed that a germline deletion of the last
two exons of TACSTD1, the gene just upstream of MSH2 encod-
ing epithelial cell adhesion molecule (EpCAM), leads to inactiva-
tion of the MSH2 gene by promoter hypermethylation exclusively
in tissues expressing EpCAM (mosaic pattern). This mechanism
may cause LS in patients with MSH2-deficient microsatellite
unstable tumours with an undetectable MSH2 germline mutation.
Identification of these cases is possible by the determination of the
methylation status of the MSH2 gene promoter in the tumour and
in EpCAM expressing normal tissues (e.g. normal colorectal
mucosa). In addition, evidence for the presence of MSH2 methy-
lation can be obtained by detection of deletions in the 3 end of the
TACSTD1 gene.
Molecular diagnostics 
of Lynch syndrome
The molecular diagnostics of LS usually starts with MSI analysis.
MSI analysis is traditionally performed with a panel of five
microsatellite markers proposed by a NCI (National Cancer
Institute) sponsored consensus conference, also known as the
Bethesda panel [29]. With these markers, microsatellites in
tumour DNA are compared to microsatellites in corresponding
DNA from normal tissue. Tumours with more than one unstable
marker (or 40% of markers) are categorized as having a high
degree of MSI (MSI-H), which is suspect for LS or epigenetic
MLH1 silencing [88–91]. Those with one unstable marker
(20–40% of markers) are categorized as having a low degree of
MSI (MSI-L) and tumours with no instability (20%) are catego-
rized as being microsatellite stable (MSS), seen in sporadic carci-
nomas [92]. Although there are no clear differences in clinical or
pathological features between MSI-L and MSS tumours, it has
been speculated that MSI-L tumours comprise an independent
phenotype [93]. However, there is nowadays no role for separat-
ing MSI-L from MSS tumours in the diagnostic work-up.
Furthermore, MSI testing seems not only important for recogni-
tion of LS, but may in the future also improve the clinical manage-
ment of CRC patients. This is because patients with microsatellite
unstable CRCs appear to have a better prognosis than patients
with MSS tumours [94–97] and they do not seem to benefit from
adjuvant chemotherapy with 5-fluorouracil [98–100].
The Bethesda panel, comprising two mononucleotide repeats
(BAT-25 and BAT-26) and three dinucleotide repeats (D2S123,
D5S346 and D17S250) [62], does have some limitations, mainly
caused by the dinucleotide repeats. These repeats are highly poly-
morphic and less sensitive and specific in the identification of
MSI-H tumours than mononucleotide repeats. Their use in MSI
screening requires analysis of corresponding germline DNA [101]
and the interpretation of size alterations in dinucleotide repeats is
more difficult due to stutter, a PCR artefact. Their use can result in
misclassification of MSI-L tumours as MSI-H [102, 103].
Furthermore, MSH6 mutation carriers may develop tumours (pre-
dominantly endometrial cancer) without alteration in these dinu-
cleotide repeats leading to false MSI-L or MSS results [104, 105].
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The limitations of the Bethesda panel have lead to the development
of a pentaplex panel, which comprises five quasi-monomorphic
mononucleotide repeats (see below). This panel shows less varia-
tion in size among different ethnic populations and has been
shown to be superior to the Bethesda panel for the detection of
MSI-H tumours [102, 106]. Because the pentaplex analysis is car-
ried out in a single multiplex PCR, this method is simple to use
and is free of errors due to mixing samples.
To gain insight into what gene might be affected in patients
with MSI-H tumours, MLH1, MSH2, MSH6 and PMS2 protein
expression can be assessed by immunohistochemistry. The com-
bination of MSI analysis and MMR protein immunostaining is gen-
erally considered as the superior strategy for the identification of
suspected LS patients [107]. Absence of MMR protein nuclear
staining within the tumour cells can be compared to nuclear stain-
ing in the normal cells within the same tumour specimen (and
same histological section). The latter then serve as internal posi-
tive control.
Due to their heterodimeric nature, different immunohistochem-
ical staining patterns of the MMR proteins can be observed 
(Table 6). Loss of MLH1 protein due to MLH1 gene mutation or
promoter hypermethylation is usually accompanied with absence
of PMS2 in the tumour (Fig. 3). Similarly, absence of MSH2 due to
MSH2 mutations results in absence of MSH6 (Fig. 3), since MSH6
and PMS2 will disintegrate without their obligatory partners MSH2
and MLH1, respectively. A mutation in either PMS2 or MSH6 does
not lead to loss of MLH1 and MSH2 protein, respectively (Fig. 3),
because of the formation of other heterodimers than MLH1-PMS2
and MSH2-MSH6. MLH1 can for instance dimerize with either
MLH3 or PMS1 [108, 109] and MSH2 can also bind to MSH3
[110]. Due to the binding of MLH1 and MSH2 to other MMR pro-
teins in the absence of PMS2 or MSH6, there is no concurrent loss
of MLH1 and MSH2 [111]. To date no bona fide involvement of
PMS1, MLH3 or MSH3 (inactivating mutations) has been demon-
strated in LS.
In general, absent MSH2, MSH6 or PMS2 expression in
tumour cells with present staining in normal cells is suspect for
underlying LS and calls for germline testing. Absent MLH1 (and
PMS2) expression can indicate either LS or a sporadic tumour
with epigenetically silenced MLH1 [111]. If epigenetic MLH1
silencing has been excluded by the analysis of MLH1 hypermethy-
lation and/or BRAF mutation analysis, MLH1 germline mutation
testing is indicated. Furthermore, it might theoretically be possible
that immunohistochemical absence of PMS2 or MSH6 without
concomitant absence of MLH1 or MSH2, respectively, is due to
mutations in MLH1 or MSH2. These mutations then will not lead
to decreased MLH1 and MSH2 immunostaining, while binding to
and expression of PMS2 and MSH6, respectively, is abrogated.
Therefore, absent PMS2 or MSH6 immunostaining without
detectable mutations in the PMS2 or MSH2 gene, asks for muta-
tion analysis of MLH1 or MSH2 respectively.
At our institution, MSI analysis and immunohistochemistry are
requested either by the pathologist when patients fulfil the criteria
as depicted in Table 5, or by the clinical geneticist (or clinician)
when individuals meet the Bethesda Guidelines. The flowchart of
the molecular diagnostics of LS in The Netherlands is depicted in
Fig. 4. All these different molecular diagnostic procedures will be
described in more detail in the next paragraphs.
Description of molecular analyses
MSI analysis
From routine formalin fixed and paraffin embedded (FFPE) tumour
tissue specimens 10 to 20 consecutive sections of 4 	m are cut
and routinely glued on microscope glass slides. The number of
sections is determined by the size of the tissue fragments that
need to be isolated for DNA analysis. All sections are deparaf-
finized and the first and the last section of the series are routine
Mayer haematoxylin and eosin stained. These sections are used as
reference for the isolated tissue parts. The intermediate sections
are stained in haematoxylin and rinsed in distilled water. The indi-
cated tumour and normal tissue fragments are then manually
scraped in distilled water from the glass slide and transferred to
Eppendorf vials. From the remaining tissue fragments on the glass
slides, routine microscopic preparations are made after additional
staining with eosin. With these preparations the isolated tissue
fragments can be verified (Fig. 5). Occasionally, when large and
easy recognizable tissue fragments can be isolated, scraping is
performed from paraffin sections on glass slides without deparaf-
finization. Furthermore, when the tissue fragments to be isolated
are too small for manual isolation, laser microdissection is used
on haematoxylin and eosin stained sections glued on membrane
containing glass slides (PALM Membrane Slides, P.A.L.M.
Microlaser Technologies AG, Bernried, Germany) (Fig. 5).
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Table 6 Immunohistochemical expression patterns associated with
MMR-gene mutations
MMR-gene mutation
MLH1 MSH2 MSH6 PMS2
Protein expression MLH1 
*   
MSH2  
  
MSH6  
 
 
PMS2 
   

* Absent MLH1 protein expression can be associated with either MLH1
germline mutations as well as epigenetic MLH1 silencing by promoter
methylation.
  present nuclear protein expression in tumour cells (as well as in
normal cells).

  absent nuclear protein expression in tumour cells (and present
staining in normal cells, thus serving as internal positive control).
J. Cell. Mol. Med. Vol 14, No 1-2, 2010
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Although MSI can be reliably detected even when DNA is iso-
lated from a tissue fragment composed of only 10% neoplastic
cells (unpublished data), tumour DNA is isolated preferably from
a tissue fragment with a high percentage (70%) of tumour cells.
DNA isolated from tissue with a high percentage of tumour cells
can also be used for reliable additional investigations (BRAF muta-
tion and MLH1 hypermethylation). In the case of an adenoma the
fragment with the highest grade of dysplasia should be used for
DNA isolation. For isolation of normal DNA a tissue fragment com-
posed of normal cells, preferably from the normal epithelial coun-
terpart of the tumour (e.g. normal colorectal or normal endome-
trial mucosa), is used to circumvent heterogeneity problems that
can be caused by mosaicism (e.g. mosaic MLH1 promoter
germline hypermethylation or MSH2 promoter hypermethylation
only in Epcam expressing cells). However, since these mosaic
phenomena are very rare, other normal tissue fragments (e.g. a
tumour-negative lymph node) can be used for normal DNA isola-
tion, in cases where there is no, or not easy to isolate, normal
mucosa available.
From the microdissected FFPE tissue fragments DNA is
extracted by addition of 100 to 200 	l (when very small tissue
fragments are used digestion is performed in a volume down to 
25 	l) lysis buffer (10 mM Tris/HCL pH 8.0, 1 mM ethylenedi-
aminetetraacetic acid [EDTA] pH 8.0, 0.01% Tween 20) containing
2 mg/ml proteinase K and 5% Chelex 100 resin. Following
overnight incubation at 56C, proteinase K is inactivated at 100C
for 10 min. Next, dissolved DNA is separated from cell debris by
centrifugation at maximum speed in a microcentrifuge for 5 min.
The DNA-containing supernatant is carefully pipetted from the
Chelex resin-containing pellet (Chelex resin inhibits polymerase
activity) and transferred to another Eppendorf vial. In case un-
deparaffinized sections were used for DNA isolation, the DNA-
containing supernatant is collected by carefully poking the pipette
tip through the solidified paraffin layer on top of the supernatant.
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Fig. 3 Five CRC cases; haematoxylin and eosin staining and MLH1, PMS2, MSH2 and MSH6 immunohistochemistry (IHC) results. Case 1: normal IHC in
the tumour cells. Case 2: absence of MLH1 and PMS2 in the tumour cells. Case 3: absence of PMS2 in the tumour cells. Case 4: absence of MSH2 and
MSH6 in the tumour cells. Case 5: absence of MSH6 in the tumour cells. Arrows point to IHC tumour cells, filled arrow heads point to IHC– tumour cells
and open arrow heads point to IHC stromal cells.
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Different methods for MSI analysis are currently available. In
our laboratory we use the MSI analysis system of Promega
(Promega, Madison, WI, USA) [103]; a fluorescent multiplex PCR-
based assay in which the PCR products are separated by capillary
electrophoresis using an ABI PRISM 3130xl genetic analyser
(Applied Biosystems, Foster City, CA, USA). PCR is performed
according to the kit instructions in a total volume of 10 	l includ-
ing 2 	l of an about 80-fold dilution of the isolated DNA solution.
The output data are analysed with GeneMarker software
(SoftGenetics, State College, PA, USA) to determine MSI status of
tumour samples. This system includes fluorescently labelled
primers for co-amplification of five quasi-monomorphic mononu-
cleotide repeat markers BAT-25, BAT-26, NR-21, NR-24 and
MONO-27. In addition, 2 pentanucleotide markers (Penta C and
Penta D) characterized by a high level of polymorphism have been
added to provide information on possible sample mix-up or con-
tamination. Because of the low size variation in the population of
the selected mononucleotide markers this analysis allows, in most
cases, that only tumour DNA is investigated for MSI. DNA from a
MSS cell line suffices as normal DNA reference. If inconclusive
results are obtained, for example due to the infrequent occurrence
of bi-allelic variation or borderline shifts of the marker peaks, the
assay is repeated with both tumour and patient matched normal
DNA. Furthermore, additional mononucleotide MSI markers such
as BAT-40 can be used in the case of a MSS tumour with a strong
clinical suspicion for underlying LS. Results of MSS and
microsatellite unstable tumours are shown in Fig. 6.
Immunohistochemistry
Our method of immunohistochemistry was described in detail pre-
viously [112]. Briefly, FFPE tissue sections (4 	m) are dewaxed,
and antigen retrieval is performed in 10 mM Tris-EDTA buffer, 
(pH 9.0) in a microwave oven for 45 min. at 100C. Primary anti-
bodies anti-MLH1 (Pharmingen BD, Alphen aan den Rijn, The
Netherlands; clone G168–728; dilution, 1:20), anti-MSH2
(Pharmingen BD; clone G219–1129; dilution, 1:300), anti-MSH6
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Fig. 4 Flowchart for molecular diagnostics of LS in The Netherlands.
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(Pharmingen BD; clone 44; dilution, 1:100) and anti-PMS2
(Pharmingen BD; clone A16–4; dilution, 1:50) are applied for 1 hr
at room temperature. After washing, immunoreactivity is visualized
with the Envision kit (Dako, Glostrup, Denmark). Subsequently,
the sections are counterstained with Mayer haematoxylin and
evaluated under a light microscope (Fig. 3).
MLH1 promoter hypermethylation assay
In case of absent MLH1 expression in tumour cells, the methyla-
tion status of the MLH1 promoter can be determined by different
methods such as methylation-specific PCR [113] and methyla-
tion-specific multiplex ligation-dependent probe amplification
(MS-MLPA) [114]. MS-MLPA is performed with the SALSA MS-
MLPA Kit ME011-A1 for MMR genes (MRC-Holland, Amsterdam,
The Netherlands). The analysis is performed according to the kit
instructions with 3 	l undiluted DNA solution as input. The assay
takes advantage of methylation-sensitive endonuclease HhaI,
which only cleaves unmethylated DNA fragments. The MS-MLPA
kit contains 8 control probe sequences and 21 methylation-sensi-
tive probes of which 5 recognize CpG dinucleotides within the
MLH1 promoter. The methylation-sensitive probes contain a
restriction site for HhaI. Comparison of a HhaI-digested DNA sam-
ple (yielding only signal of methylated DNA) to its undigested
counterpart (yielding signal of both methylated and unmethylated
DNA) provides insight into the degree of methylation. Details of
the MS-MLPA protocol are freely available on the website of the
manufacturer (http://www.mrc-holland.com).
Basically, tumour DNA is hybridized to the probe mix. After
hybridization, half of the sample is subjected to a ligation step
joining both adjacently hybridized fragments of a probe set,
whereas the other half of the sample is subjected to both ligation
and HhaI digestion, leaving only methylated sequences intact.
Subsequent PCR amplification exponentially amplifies all ligated,
but undigested, probes. The signal generated with the part of the
sample that has undergone both ligation and digestion represents
the amount of methylated DNA present in the tumour. For frag-
ment analysis, PCR products are separated by capillary gel elec-
trophoresis using an ABI PRISM 3130xl genetic analyser (Applied
Biosystems) and quantified with GeneMarker software version 1.7
(SoftGenetics). The MS-MLPA results are normalized by dividing
the peak height of each MLH1 probe signal by the mean peak
height of the eight control fragments obtained with the same sam-
ple (Fig. 7). The degree of methylation for individual MLH1 probes
can be assessed by dividing normalized values of each MLH1
probe within digested DNA samples by normalized values of the
probe in corresponding undigested samples. The MS-MLPA assay
is performed with both tumour and normal mucosal DNA to detect
possible germline MLH1 promoter hypermethylation.
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Fig. 5 (A, B, C) Manual macrodissection of a normal tissue fragment (arrow) and a region of the tumour composed of a high percentage of tumour cells
(arrow head), before, during and after macrodissection, respectively. (D, E, F) Laser capture microdissection of a small tumour tissue fragment sur-
rounded by abundant stromal cells, before, during and after laser capture microdissection, respectively. Insert in (F) shows the microdissected fragment.
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BRAF mutation analysis
BRAF alterations of mutational hotspot codon V600 are deter-
mined by bi-directional cycle sequencing of PCR-amplified frag-
ments. PCR amplification is performed by M13-tailed forward
primer 5-TGT AAA ACG ACG GCC AGT AAA CTC TTC ATA ATG
CTT GCT CTG -3 and M13-tailed reverse primer 5-CAG GAA ACA
GCT ATG ACC GGC CAA AAA TTT AAT CAG TGG AA-3. PCR prod-
ucts are generated in a 15 	l reaction mixture including 1.0 	l
undiluted DNA solution, 10 	mol of each primer, 25 mM MgCl2,
10 mM dNTPs and 1 U Taq polymerase (Promega). The PCR reac-
tion is performed with a thermocycler (Biometra, Gˆttingen,
Germany) with an initial denaturating step (95C) for 3 min., fol-
lowed by 35 cycles consisting of denaturation (95C) for 30 sec.,
annealing (60C) for 45 sec. and extension (72C) for 45 sec. After
the final cycle, an extension period of 10 min. at 72C is per-
formed. The PCR products are sequenced with M13 forward
primer 5-TGT AAA ACG ACG GCC AGT-3 and M13 reverse primer
5-CAG GAA ACA GCT ATG ACC-3 using the ABI PRISM BigDye
Terminator v3.1 kit (Applied Biosystems). Sequence analyses are
performed on an ABI PRISM 3130xl genetic analyser (Applied
Biosystems). Samples are analysed using Mutation Surveyor soft-
ware (SoftGenetics) and are compared with the public sequence of
GenBank (NT_007914). Examples of BRAF mutation analysis
results are shown in Fig. 8.
Limitations of molecular analyses
Over the last decade, the diagnostics of LS have improved con-
siderably. Nevertheless, there still remain some limitations that
need to be addressed. It has to be taken into account that the
described procedures provide information on the chance that a
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Fig. 6 MSI analysis of four cases of
paired normal (N) and tumour (T)
DNA. (A) Case 1: N1 and T1, CRC
no MSI: MSS. Case 2: N2 and T2,
CRC demonstrates clear MSI. (B)
Case 3: N3 and T3, endometrial car-
cinoma with MSI (subtle
microsatellite shifts). Case 4: N4
and T4, CRC without MSI but with
heterozygous NR-21 microsatellite
alleles (present in normal and
tumour DNA). Arrow heads indicate
the MSI shifts, arrows indicate the
variant NR-21 allele.
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certain tumour arose in the context of LS and are not diagnostic
for LS in an absolute sense. The false negative rate of MSI analy-
sis is very low (5%) but cannot be completely ruled out. MSI
can be very subtle or escape detection particularly in low grade
lesions as adenomas, in endometrial carcinomas (Fig. 6B, panel
N3/T3) and in samples with a low percentage of neoplastic cells
[115]. These false-negative results may lead to the exclusion 
of LS patients (and affected family members) from necessary
surveillance programs and subsequent failure to detect (sec-
ondary) cancers in an early stage. In addition, although rare, 
sporadic MSS tumours can occur in LS patients and MSI analy-
sis then fails to indicate LS. To exclude false-negative MSI
results as much as possible it is necessary to isolate DNA from
a tissue fragment with a high percentage of tumour cells. For
this, laser microdissection might be preferable instead of man-
ual microdissection. However, laser microdissection is a time
consuming and labour-intensive procedure to obtain sufficient
tissue fragments for DNA isolation [116]. In general, it is recom-
mended to refer patients with a high clinical or familial suspicion
of LS to a clinical genetics department, irrespective of the MSI
status. In addition, other hereditary CRC syndromes such as
attenuated familial adenomatous polyposis, MYH-associated
polyposis, Cowden syndrome or Peutz-Jeghers syndrome might
need to be excluded.
Although the assessment of MMR-protein expression by
immunohistochemistry is a fast and simple procedure, the inter-
pretation of the results can be difficult. Interpretation may be
impeded by absence or low intensity of the nuclear staining in
tumour and normal tissue due to fixation artefacts, especially in
old archival specimens [117]. In case of missense mutations, the
inactive protein may be (partly) expressed and detectable by
immunohistochemistry. The interpretation is also hampered by
some degree of observer-variation and the value of immunohisto-
chemistry partially depends on the experience of the pathologist
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Fig. 6 Continued
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[118, 119]. For these reasons immunohistochemistry cannot
replace MSI testing to detect LS, and this underlines the impor-
tance of the combined application of MSI analysis and MMR 
protein immunostaining to detect LS.
In the evaluation of MLH1 promoter methylation, it is impor-
tant to study the correct promoter regions since MLH1 expression
only correlates with methylation of the proximal promoter regions
(mainly region C, but also region D) [113, 120, 121]. Nevertheless,
there are still studies published in which the distal MLH1 promoter
regions were analysed, which are not or only poorly associated
with gene silencing. Moreover, epigenetic inactivation of the sec-
ond normal MLH1 allele by promoter methylation (second hit),
may also play a role in individuals with LS [122, 123], and it
should be realized that the detection of MLH1 promoter methyla-
tion can not completely rule out LS. In the case of a strong clini-
cal suspicion, referral to a clinical geneticist is indicated. The exact
frequencies of MLH1 promoter methylation in LS patients (either
as a second inactivating event, or as a heritable germline epimu-
tation), are unknown. It has been reported that in tumours from
MLH1 mutation carriers, the wild-type allele is hypermethylated in
0–46% of the tumours [65, 76, 80, 122, 124–129]. However, only
one study evaluated the proximal promoter region (region D)
associated with gene silencing in 55 CRCs and endometrial can-
cers of MLH1 germline mutation carriers [129]. Hypermethylation
was seen in 7.3% of all tumours (16% of CRCs). In the other 
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Fig. 8 Mutation analysis of codon 600 of the BRAF gene. (A) Tumour DNA
without BRAF codon 600 mutation. (B) Tumour DNA with a heterozygous
oncogenic mutation GTG-GAG, leading to a V600E amino acid substitution.
Fig. 7 MLH1 promoter hyperme-
thylation assay; MS-MLPA analysis
of a MSI CRC with absence of
MLH1 and PMS2 expression.
Results are shown of paired undi-
gested normal (Nu) and undigested
tumour (Tu) DNA and of the methy-
lation-sensitive endonuclease HhaI
digested normal (Nd) and tumour
(Td) DNA. Arrows indicate six
MLH1 promoter probes, nr 1 repre-
sentative for a fragment without
and nrs 2–6 representative for frag-
ments with a HhaI restriction site.
In the HhaI digested DNA, probes
2–6 are clearly present in the
tumour DNA (Td) and not in the
paired normal DNA (Nd) indicating
tumour-specific methylation of the
MLH1 promoter fragments 2–6.
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studies, promoter regions not associated with MLH1 silencing
were investigated (i.e. the distal promoter regions) [65, 76, 80,
122, 124–128].
There are some other points of concern in the molecular diag-
nostics of LS. First, the value of MSI testing and immunohisto-
chemistry in other LS-related tumours than CRC is largely
unknown [130]. In endometrial tumours, the second most com-
mon malignancy in LS, MSI can escape detection by the occur-
rence of only subtle shifts in the size of the markers [131].
Therefore, MSI analysis in endometrial cancers is performed with
patient matched normal DNA as the reference, and molecular pre-
screening has been found feasible [4, 132, 133] (Fig. 6B, panel
N3/T3). Furthermore, the quality of DNA extracted from FFPE
tumours can occasionally be poor and therefore not suitable for
MSI analysis [130]. And last but not least, some individuals might
have ethical objections against MSI testing or immunohistochem-
istry, since the diagnosis of LS can be very likely after the
described molecular examinations, which might have negative
social consequences and raise concerns e.g. about insurance
risks. Therefore, we believe that the clinician should inform the
patient about the fact that the pathological examinations may not
only give information about the nature of the tumour, but may also
indicate an elevated risk of an underlying hereditary disorder.
Conclusions
Different diagnostic strategies have been developed for LS as dis-
cussed in this review and the optimal method for the identification
of LS patients is still debated and in flux. In the previous paragraphs
the molecular diagnostic approach of LS in The Netherlands
(Erasmus MC, University Medical Center, Rotterdam) has been
described (Fig. 4). This approach combines MSI analysis and MMR
protein immunostaining and is in our opinion a productive way of
pre-selecting patients for germline mutation analysis, with a central
role for the pathologist. Nevertheless, if the clinical suspicion for LS
is very high, e.g. because of a positive family history for LS-associ-
ated cancers or a LS-associated malignancy diagnosed at a very
young age, referral to a clinical geneticist is strongly recommended,
even in the case of tumours without MMR deficiency (i.e. MSS).
Acknowledgements
The currently ongoing LIMO study is supported by an Erasmus MC-grant.
We thank Frank van der Panne for photographic work.
References
1. Boyle P, Ferlay J. Cancer incidence and
mortality in Europe, 2004. Ann Oncol.
2005; 16: 481–8.
2. Aaltonen LA, Salovaara R, Kristo P, et al.
Incidence of hereditary nonpolyposis col-
orectal cancer and the feasibility of molec-
ular screening for the disease. N Engl J
Med. 1998; 338: 1481–7.
3. Hampel H, Frankel WL, Martin E, et al.
Feasibility of screening for Lynch syn-
drome among patients with colorectal can-
cer. J Clin Oncol. 2008; 26: 5783–8.
4. Hampel H, Frankel W, Panescu J, et al.
Screening for Lynch syndrome (hereditary
nonpolyposis colorectal cancer) among
endometrial cancer patients. Cancer Res.
2006; 66: 7810–7.
5. Lynch HT, Smyrk TC, Watson P, et al.
Genetics, natural history, tumor spectrum,
and pathology of hereditary nonpolyposis
colorectal cancer: an updated review.
Gastroenterology. 1993; 104: 1535–49.
6. Watson P, Lynch HT. Extracolonic cancer
in hereditary nonpolyposis colorectal can-
cer. Cancer. 1993; 71: 677–85.
7. Quehenberger F, Vasen HF, van
Houwelingen HC. Risk of colorectal and
endometrial cancer for carriers of muta-
tions of the hMLH1 and hMSH2 gene: cor-
rection for ascertainment. J Med Genet.
2005; 42: 491–6.
8. Vasen HF, Wijnen JT, Menko FH, et al.
Cancer risk in families with hereditary non-
polyposis colorectal cancer diagnosed by
mutation analysis. Gastroenterology.
1996; 110: 1020–7.
9. Plaschke J, Engel C, Kruger S, et al. Lower
incidence of colorectal cancer and later age
of disease onset in 27 families with patho-
genic MSH6 germline mutations compared
with families with MLH1 or MSH2 muta-
tions: the German Hereditary Nonpolyposis
Colorectal Cancer Consortium. J Clin Oncol.
2004; 22: 4486–94.
10. Aarnio M, Sankila R, Pukkala E, et al.
Cancer risk in mutation carriers of DNA-
mismatch-repair genes. Int J Cancer.
1999; 81: 214–8.
11. Vasen HF, Stormorken A, Menko FH, 
et al. MSH2 mutation carriers are at higher
risk of cancer than MLH1 mutation carri-
ers: a study of hereditary nonpolyposis
colorectal cancer families. J Clin Oncol.
2001; 19: 4074–80.
12. Hendriks YM, Wagner A, Morreau H, et al.
Cancer risk in hereditary nonpolyposis
 colorectal cancer due to MSH6 mutations:
impact on counseling and surveillance.
Gastroenterology. 2004; 127: 17–25.
13. Hampel H, Stephens JA, Pukkala E, et al.
Cancer risk in hereditary nonpolyposis col-
orectal cancer syndrome: later age of onset.
Gastroenterology. 2005; 129: 415–21.
14. Senter L, Clendenning M, Sotamaa K, 
et al. The clinical phenotype of Lynch syn-
drome due to germ-line PMS2 mutations.
Gastroenterology. 2008; 135: 419–28.
15. Lynch HT, de la Chapelle A. Genetic sus-
ceptibility to non-polyposis colorectal can-
cer. J Med Genet. 1999; 36: 801–18.
16. Boland CR. Evolution of the nomenclature
for the hereditary colorectal cancer syn-
dromes. Fam Cancer. 2005; 4: 211–8.
17. Jarvinen HJ, Aarnio M, Mustonen H, 
et al. Controlled 15-year trial on screening
for colorectal cancer in families with
hereditary nonpolyposis colorectal cancer.
Gastroenterology. 2000; 118: 829–34.
18. de Jong AE, Hendriks YM, Kleibeuker JH,
et al. Decrease in mortality in Lynch syn-
drome families because of surveillance.
Gastroenterology. 2006; 130: 665–71.
19. Stupart DA, Goldberg PA, Algar U, et al.
Surveillance colonoscopy improves
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
194
 survival in a cohort of subjects with a sin-
gle mismatch repair gene mutation.
Colorectal Dis. 2009; 11: 126–30.
20. Schmeler KM, Lynch HT, Chen LM, et al.
Prophylactic surgery to reduce the risk of
gynecologic cancers in the Lynch syn-
drome. N Engl J Med. 2006; 354: 261–9.
21. Vasen HF, Mecklin JP, Khan PM, et al.
The International Collaborative Group on
Hereditary Non-Polyposis Colorectal
Cancer (ICG-HNPCC). Dis Colon Rectum.
1991; 34: 424–5.
22. Kievit W, de Bruin JH, Adang EM, et al.
Current clinical selection strategies for
identification of hereditary non-polyposis
colorectal cancer families are inadequate: a
meta-analysis. Clin Genet. 2004; 65:
308–16.
23. Vasen HF, Watson P, Mecklin JP, et al.
New clinical criteria for hereditary nonpoly-
posis colorectal cancer (HNPCC, Lynch
syndrome) proposed by the International
Collaborative group on HNPCC.
Gastroenterology. 1999; 116: 1453–6.
24. Lindor NM, Petersen GM, Hadley DW, 
et al. Recommendations for the care of
individuals with an inherited predisposition
to Lynch syndrome: a systematic review.
JAMA. 2006; 296: 1507–17.
25. Church J, McGannon E. Family history of
colorectal cancer: how often and how
accurately is it recorded? Dis Colon
Rectum. 2000; 43: 1540–4.
26. Katballe N, Juul S, Christensen M, et al.
Patient accuracy of reporting on hereditary
non-polyposis colorectal cancer-related
malignancy in family members. Br J Surg.
2001; 88: 1228–33.
27. Sijmons RH, Boonstra AE, Reefhuis J, 
et al. Accuracy of family history of cancer:
clinical genetic implications. Eur J Hum
Genet. 2000; 8: 181–6.
28. Rodriguez-Bigas MA, Boland CR,
Hamilton SR, et al. A National Cancer
Institute Workshop on Hereditary
Nonpolyposis Colorectal Cancer
Syndrome: meeting highlights and
Bethesda guidelines. J Natl Cancer Inst.
1997; 89: 1758–62.
29. Umar A, Boland CR, Terdiman JP, et al.
Revised Bethesda Guidelines for hereditary
nonpolyposis colorectal cancer (Lynch
syndrome) and microsatellite instability. 
J Natl Cancer Inst. 2004; 96: 261–8.
30. Jenkins MA, Hayashi S, O’Shea AM, 
et al. Pathology features in Bethesda
guidelines predict colorectal cancer
microsatellite instability: a population-
based study. Gastroenterology. 2007; 133:
48–56.
31. Truta B, Chen YY, Blanco AM, et al.
Tumor histology helps to identify Lynch
syndrome among colorectal cancer
patients. Fam Cancer. 2008; 7: 267–74.
32. Sanchez JA, Vogel JD, Kalady MF, et al.
Identifying Lynch syndrome: we are all
responsible. Dis Colon Rectum. 2008; 51:
1750–6.
33. Wolf B, Gruber S, Henglmueller S, et al.
Efficiency of the revised Bethesda guide-
lines (2003) for the detection of mutations
in mismatch repair genes in Austrian
HNPCC patients. Int J Cancer. 2006; 118:
1465–70.
34. Pinol V, Castells A, Andreu M, et al.
Accuracy of revised Bethesda guidelines,
microsatellite instability, and immunohis-
tochemistry for the identification of
patients with hereditary nonpolyposis col-
orectal cancer. JAMA. 2005; 293:
1986–94.
35. Rodriguez-Moranta F, Castells A, Andreu
M, et al. Clinical performance of original
and revised Bethesda guidelines for the
identification of MSH2/MLH1 gene carriers
in patients with newly diagnosed colorectal
cancer: proposal of a new and simpler set
of recommendations. Am J Gastroenterol.
2006; 101: 1104–11.
36. Balmana J, Balaguer F, Castellvi-Bel S,
et al. Comparison of predictive models,
clinical criteria and molecular tumour
screening for the identification of patients
with Lynch syndrome in a population-
based cohort of colorectal cancer patients.
J Med Genet. 2008; 45: 557–63.
37. Ramsoekh D, Wagner A, van Leerdam
ME, et al. A high incidence of MSH6 muta-
tions in Amsterdam criteria II-negative
families tested in a diagnostic setting. Gut.
2008; 57: 1539–44.
38. van Dijk DA, Oostindier MJ,
Kloosterman-Boele WM, et al. Family
history is neglected in the work-up of
patients with colorectal cancer: a quality
assessment using cancer registry data.
Fam Cancer. 2007; 6: 131–4.
39. Overbeek LI, Hoogerbrugge N, van
Krieken JH, et al. Most patients with col-
orectal tumors at young age do not visit a
cancer genetics clinic. Dis Colon Rectum.
2008; 51: 1249–54.
40. Van Lier MG, De Wilt JH, Wagemakers
JJ, et al. Underutilization of microsatel-
lite instability analysis in colorectal can-
cer patients at high risk for Lynch syn-
drome. Scand J Gastroenterol. 2009; 44:
600–4.
41. Kievit W, de Bruin JH, Adang EM, et al.
Cost effectiveness of a new strategy to
identify HNPCC patients. Gut. 2005; 54:
97–102.
42. de Bruin JH, Ligtenberg MJ, Nagengast
FM, et al. Optimizing the detection of
hereditary non-polyposis colorectal can-
cer: an update. Scand J Gastroenterol
Suppl. 2006; 243: 146–52.
43. Wijnen JT, Vasen HF, Khan PM, et al.
Clinical findings with implications for
genetic testing in families with clustering
of colorectal cancer. N Engl J Med. 1998;
339: 511–8.
44. Barnetson RA, Tenesa A, Farrington SM,
et al. Identification and survival of carriers
of mutations in DNA mismatch-repair
genes in colon cancer. N Engl J Med. 2006;
354: 2751–63.
45. Balmana J, Stockwell DH, Steyerberg
EW, et al. Prediction of MLH1 and MSH2
mutations in Lynch syndrome. JAMA.
2006; 296: 1469–78.
46. Chen S, Wang W, Lee S, et al. Prediction
of germline mutations and cancer risk in
the Lynch syndrome. JAMA. 2006; 296:
1479–87.
47. Peltomaki P, Vasen H. Mutations associ-
ated with HNPCC predisposition–Update of
ICG-HNPCC/INSiGHT mutation database.
Dis Markers. 2004; 20: 269–76.
48. Vasen HF, Boland CR. Progress in genetic
testing, classification, and identification of
Lynch syndrome. JAMA. 2005; 293:
2028–30.
49. Miyaki M, Konishi M, Tanaka K, et al.
Germline mutation of MSH6 as the cause
of hereditary nonpolyposis colorectal can-
cer. Nat Genet. 1997; 17: 271–2.
50. Hendriks YM, Jagmohan-Changur S, van
der Klift HM, et al. Heterozygous muta-
tions in PMS2 cause hereditary nonpoly-
posis colorectal carcinoma (Lynch syn-
drome). Gastroenterology. 2006; 130:
312–22.
51. Knudson AG. Two genetic hits (more or
less) to cancer. Nat Rev Cancer. 2001; 1:
157–62.
52. Chung DC, Rustgi AK. DNA mismatch
repair and cancer. Gastroenterology. 1995;
109: 1685–99.
53. Papadopoulos N, Nicolaides NC, Liu B,
et al. Mutations of GTBP in genetically
unstable cells. Science. 1995; 268:
1915–7.
54. Baker SM, Bronner CE, Zhang L, et al.
Male mice defective in the DNA mismatch
repair gene PMS2 exhibit abnormal chro-
mosome synapsis in meiosis. Cell. 1995;
82: 309–19.
55. Fishel R, Ewel A, Lescoe MK. Purified
human MSH2 protein binds to DNA
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 14, No 1-2, 2010
195
 containing mismatched nucleotides.
Cancer Res. 1994; 54: 5539–42.
56. Yang Q, Zhang R, Wang XW, et al. The
mismatch DNA repair heterodimer,
hMSH2/6, regulates BLM helicase.
Oncogene. 2004; 23: 3749–56.
57. Genschel J, Bazemore LR, Modrich P.
Human exonuclease I is required for 5 and
3 mismatch repair. J Biol Chem. 2002;
277: 13302–11.
58. Gruber SB. New developments in Lynch
syndrome (hereditary nonpolyposis col-
orectal cancer) and mismatch repair gene
testing. Gastroenterology. 2006; 130:
577–87.
59. Ionov Y, Peinado MA, Malkhosyan S, 
et al. Ubiquitous somatic mutations in
simple repeated sequences reveal a new
mechanism for colonic carcinogenesis.
Nature. 1993; 363: 558–61.
60. Umar A, Boyer JC, Thomas DC, et al.
Defective mismatch repair in extracts of
colorectal and endometrial cancer cell
lines exhibiting microsatellite instability. 
J Biol Chem. 1994; 269: 14367–70.
61. Aaltonen LA, Peltomaki P, Mecklin JP, 
et al. Replication errors in benign and
malignant tumors from hereditary non-
polyposis colorectal cancer patients.
Cancer Res. 1994; 54: 1645–8.
62. Boland CR, Thibodeau SN, Hamilton SR,
et al. A National Cancer Institute
Workshop on Microsatellite Instability for
cancer detection and familial predisposi-
tion: development of international criteria
for the determination of microsatellite
instability in colorectal cancer. Cancer Res.
1998; 58: 5248–57.
63. Lynch HT, de la Chapelle A. Hereditary
colorectal cancer. N Engl J Med. 2003;
348: 919–32.
64. Kane MF, Loda M, Gaida GM, et al.
Methylation of the hMLH1 promoter corre-
lates with lack of expression of hMLH1 in
sporadic colon tumors and mismatch
repair-defective human tumor cell lines.
Cancer Res. 1997; 57: 808–11.
65. Herman JG, Umar A, Polyak K, et al.
Incidence and functional consequences of
hMLH1 promoter hypermethylation in col-
orectal carcinoma. Proc Natl Acad Sci
USA. 1998; 95: 6870–5.
66. Herman JG, Baylin SB. Gene silencing in
cancer in association with promoter hyper-
methylation. N Engl J Med. 2003; 349:
2042–54.
67. Wang L, Cunningham JM, Winters JL, 
et al. BRAF mutations in colon cancer are
not likely attributable to defective DNA
mismatch repair. Cancer Res. 2003; 63:
5209–12.
68. Miyaki M, Iijima T, Yamaguchi T, et al.
Both BRAF and KRAS mutations are rare in
colorectal carcinomas from patients with
hereditary nonpolyposis colorectal cancer.
Cancer Lett. 2004; 211: 105–9.
69. McGivern A, Wynter CV, Whitehall VL, 
et al. Promoter hypermethylation fre-
quency and BRAF mutations distinguish
hereditary non-polyposis colon cancer
from sporadic MSI-H colon cancer. Fam
Cancer. 2004; 3: 101–7.
70. Kambara T, Simms LA, Whitehall VL, 
et al. BRAF mutation is associated with
DNA methylation in serrated polyps and
cancers of the colorectum. Gut. 2004; 53:
1137–44.
71. Domingo E, Laiho P, Ollikainen M, et al.
BRAF screening as a low-cost effective
strategy for simplifying HNPCC genetic
testing. J Med Genet. 2004; 41: 664–8.
72. Deng G, Bell I, Crawley S, et al. BRAF
mutation is frequently present in sporadic
colorectal cancer with methylated hMLH1,
but not in hereditary nonpolyposis col-
orectal cancer. Clin Cancer Res. 2004; 10:
191–5.
73. Young J, Barker MA, Simms LA, et al.
Evidence for BRAF mutation and variable
levels of microsatellite instability in a
syndrome of familial colorectal cancer.
Clin Gastroenterol Hepatol. 2005; 3:
254–63.
74. Loughrey MB, Waring PM, Tan A, et al.
Incorporation of somatic BRAF mutation
testing into an algorithm for the investiga-
tion of hereditary non-polyposis colorectal
cancer. Fam Cancer. 2007; 6: 301–10.
75. Bessa X, Balleste B, Andreu M, et al. A
prospective, multicenter, population-based
study of BRAF mutational analysis for
Lynch syndrome screening. Clin
Gastroenterol Hepatol. 2008; 6: 206–14.
76. Nagasaka T, Koi M, Kloor M, et al.
Mutations in both KRAS and BRAF may
contribute to the methylator phenotype in
colon cancer. Gastroenterology. 2008;
134: 1950–60, 1960.
77. Grady WM, Carethers JM. Genomic and
epigenetic instability in colorectal cancer
pathogenesis. Gastroenterology. 2008;
135: 1079–99.
78. Gazzoli I, Loda M, Garber J, et al. A
hereditary nonpolyposis colorectal carci-
noma case associated with hypermethyla-
tion of the MLH1 gene in normal tissue and
loss of heterozygosity of the unmethylated
allele in the resulting microsatellite insta-
bility-high tumor. Cancer Res. 2002; 62:
3925–8.
79. Suter CM, Martin DI, Ward RL. Germline
epimutation of MLH1 in individuals with
multiple cancers. Nat Genet. 2004; 36:
497–501.
80. Miyakura Y, Sugano K, Akasu T, et al.
Extensive but hemiallelic methylation of
the hMLH1 promoter region in early-onset
sporadic colon cancers with microsatellite
instability. Clin Gastroenterol Hepatol.
2004; 2: 147–56.
81. Hitchins M, Williams R, Cheong K, et al.
MLH1 germline epimutations as a factor in
hereditary nonpolyposis colorectal cancer.
Gastroenterology. 2005; 129: 1392–9.
82. Hitchins MP, Wong JJ, Suthers G, et al.
Inheritance of a cancer-associated MLH1
germ-line epimutation. N Engl J Med.
2007; 356: 697–705.
83. Valle L, Carbonell P, Fernandez V, et al.
MLH1 germline epimutations in selected
patients with early-onset non-polyposis
colorectal cancer. Clin Genet. 2007; 71:
232–7.
84. Morak M, Schackert HK, Rahner N, et al.
Further evidence for heritability of an
epimutation in one of 12 cases with MLH1
promoter methylation in blood cells clini-
cally displaying HNPCC. Eur J Hum Genet.
2008; 16: 804–11.
85. Hitchins MP, Ward RL. Constitutional
(germline) MLH1 epimutation as an
 aetiological mechanism for hereditary non-
polyposis colorectal cancer. J Med Genet.
2009; 46: 793–802.
86. Dobrovic A, Kristensen LS. DNA methyla-
tion, epimutations and cancer predisposi-
tion. Int J Biochem Cell Biol. 2009; 41:
34–9.
87. Ligtenberg MJ, Kuiper RP, Chan TL, 
et al. Heritable somatic methylation and
inactivation of MSH2 in families with
Lynch syndrome due to deletion of the 3’
exons of TACSTD1. Nat Genet. 2009; 41:
112–7.
88. Dietmaier W, Wallinger S, Bocker T, 
et al. Diagnostic microsatellite instability:
definition and correlation with mismatch
repair protein expression. Cancer Res.
1997; 57: 4749–56.
89. Thibodeau SN, French AJ, Cunningham
JM, et al. Microsatellite instability in col-
orectal cancer: different mutator pheno-
types and the principal involvement of
hMLH1. Cancer Res. 1998; 58: 1713–8.
90. Veigl ML, Kasturi L, Olechnowicz J, et al.
Biallelic inactivation of hMLH1 by epige-
netic gene silencing, a novel mechanism
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
196
causing human MSI cancers. Proc Natl
Acad Sci USA. 1998; 95: 8698–702.
91. Jass JR, Walsh MD, Barker M, et al.
Distinction between familial and sporadic
forms of colorectal cancer showing DNA
microsatellite instability. Eur J Cancer.
2002; 38: 858–66.
92. Laiho P, Launonen V, Lahermo P, et al.
Low-level microsatellite instability in most
colorectal carcinomas. Cancer Res. 2002;
62: 1166–70.
93. Pawlik TM, Raut CP, Rodriguez-Bigas
MA. Colorectal carcinogenesis: MSI-H ver-
sus MSI-L. Dis Markers. 2004; 20:
199–206.
94. Gryfe R, Kim H, Hsieh ET, et al. Tumor
microsatellite instability and clinical out-
come in young patients with colorectal
cancer. N Engl J Med. 2000; 342: 69–77.
95. Wright CM, Dent OF, Barker M, et al.
Prognostic significance of extensive
microsatellite instability in sporadic clini-
copathological stage C colorectal cancer.
Br J Surg. 2000; 87: 1197–202.
96. Chang EY, Dorsey PB, Frankhouse J, 
et al. Combination of microsatellite insta-
bility and lymphocytic infiltrate as a prog-
nostic indicator in colon cancer. Arch Surg.
2009; 144: 511–5.
97. Thibodeau SN, Bren G, Schaid D.
Microsatellite instability in cancer of the
proximal colon. Science. 1993; 260:
816–9.
98. Ribic CM, Sargent DJ, Moore MJ, et al.
Tumor microsatellite-instability status as a
predictor of benefit from fluorouracil-
based adjuvant chemotherapy for colon
cancer. N Engl J Med. 2003; 349: 247–57.
99. Popat S, Hubner R, Houlston RS.
Systematic review of microsatellite insta-
bility and colorectal cancer prognosis. 
J Clin Oncol. 2005; 23: 609–18.
100. Jover R, Zapater P, Castells A, et al.
Mismatch repair status in the prediction of
benefit from adjuvant fluorouracil
chemotherapy in colorectal cancer. Gut.
2006; 55: 848–55.
101. Chialina SG, Fornes C, Landi C, et al.
Microsatellite instability analysis in heredi-
tary non-polyposis colon cancer using the
Bethesda consensus panel of microsatel-
lite markers in the absence of proband
normal tissue. BMC Med Genet. 2006; 7: 5.
102. Suraweera N, Duval A, Reperant M, 
et al. Evaluation of tumor microsatellite
instability using five quasimonomorphic
mononucleotide repeats and pentaplex
PCR. Gastroenterology. 2002; 123:
1804–11.
103. Bacher JW, Flanagan LA, Smalley RL, 
et al. Development of a fluorescent multi-
plex assay for detection of MSI-High
tumors. Dis Markers. 2004; 20: 237–50.
104. Akiyama Y, Sato H, Yamada T, et al.
Germ-line mutation of the hMSH6/GTBP
gene in an atypical hereditary nonpolypo-
sis colorectal cancer kindred. Cancer Res.
1997; 57: 3920–3.
105. Berends MJ, Wu Y, Sijmons RH, et al.
Molecular and clinical characteristics of
MSH6 variants: an analysis of 25 index
carriers of a germline variant. Am J Hum
Genet. 2002; 70: 26–37.
106. Xicola RM, Llor X, Pons E, et al.
Performance of different microsatellite
marker panels for detection of mismatch
repair-deficient colorectal tumors. J Natl
Cancer Inst. 2007; 99: 244–52.
107. Halvarsson B, Lindblom A, Rambech E,
et al. Microsatellite instability analysis
and/or immunostaining for the diagnosis
of hereditary nonpolyposis colorectal
cancer? Virchows Arch. 2004; 444:
135–41.
108. Chen PC, Dudley S, Hagen W, et al.
Contributions by MutL homologues Mlh3
and Pms2 to DNA mismatch repair and
tumor suppression in the mouse. Cancer
Res. 2005; 65: 8662–70.
109. Cannavo E, Marra G, Sabates-Bellver J,
et al. Expression of the MutL homologue
hMLH3 in human cells and its role in DNA
mismatch repair. Cancer Res. 2005; 65:
10759–66.
110. Acharya S, Wilson T, Gradia S, et al.
hMSH2 forms specific mispair-binding
complexes with hMSH3 and hMSH6.
Proc Natl Acad Sci USA. 1996; 93:
13629–34.
111. Shia J. Immunohistochemistry versus
microsatellite instability testing for screen-
ing colorectal cancer patients at risk for
hereditary nonpolyposis colorectal cancer
syndrome. Part I. The utility of immuno-
histochemistry. J Mol Diagn. 2008; 10:
293–300.
112. Poley JW, Wagner A, Hoogmans MM, 
et al. Biallelic germline mutations of mis-
match-repair genes: a possible cause for
multiple pediatric malignancies. Cancer.
2007; 109: 2349–56.
113. Capel E, Flejou JF, Hamelin R.
Assessment of MLH1 promoter methyla-
tion in relation to gene expression requires
specific analysis. Oncogene. 2007; 26:
7596–600.
114. Schouten JP, McElgunn CJ, Waaijer R, 
et al. Relative quantification of 40 nucleic
acid sequences by multiplex ligation-
dependent probe amplification. Nucleic
Acids Res. 2002; 30: e57.
115. Heinmoller E, Renke B, Beyser K, et al.
Pitfalls in diagnostic molecular pathol-
ogy–significance of sampling error.
Virchows Arch. 2001; 439: 504–11.
116. Muller A, Giuffre G, Edmonston TB, et al.
Challenges and pitfalls in HNPCC screen-
ing by microsatellite analysis and immuno-
histochemistry. J Mol Diagn. 2004; 6:
308–15.
117. Mangold E, Pagenstecher C, Friedl W, 
et al. Tumours from MSH2 mutation car-
riers show loss of MSH2 expression but
many tumours from MLH1 mutation car-
riers exhibit weak positive MLH1 staining. 
J Pathol. 2005; 207: 385–95.
118. Muller W, Burgart LJ, Krause-Paulus R,
et al. The reliability of immunohistochem-
istry as a prescreening method for the
diagnosis of hereditary nonpolyposis col-
orectal cancer (HNPCC)–results of an
international collaborative study. Fam
Cancer. 2001; 1: 87–92.
119. Overbeek LI, Ligtenberg MJ, Willems
RW, et al. Interpretation of immunohis-
tochemistry for mismatch repair pro-
teins is only reliable in a specialized set-
ting. Am J Surg Pathol. 2008; 32:
1246–51.
120. Matsubara N. Diagnostic application of
hMLH1 methylation in hereditary non-
polyposis colorectal cancer. Dis Markers.
2004; 20: 277–82.
121. Deng G, Chen A, Hong J, et al.
Methylation of CpG in a small region of the
hMLH1 promoter invariably correlates with
the absence of gene expression. Cancer
Res. 1999; 59: 2029–33.
122. Esteller M, Fraga MF, Guo M, et al. DNA
methylation patterns in hereditary human
cancers mimic sporadic tumorigenesis.
Hum Mol Genet. 2001; 10: 3001–7.
123. Rahner N, Friedrichs N, Steinke V, et al.
Coexisting somatic promoter hypermethy-
lation and pathogenic MLH1 germline
mutation in Lynch syndrome. J Pathol.
2008; 214: 10–6.
124. Cunningham JM, Christensen ER, Tester
DJ, et al. Hypermethylation of the hMLH1
promoter in colon cancer with microsatel-
lite instability. Cancer Res. 1998; 58:
3455–60.
125. Kuismanen SA, Holmberg MT, Salovaara
R, et al. Epigenetic phenotypes distin-
guish microsatellite-stable and -unstable
colorectal cancers. Proc Natl Acad Sci
USA. 1999; 96: 12661–6.
© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
J. Cell. Mol. Med. Vol 14, No 1-2, 2010
197© 2009 The Authors
Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
126. Kuismanen SA, Holmberg MT, Salovaara
R, et al. Genetic and epigenetic modifi-
cation of MLH1 accounts for a major
share of microsatellite-unstable colorec-
tal cancers. Am J Pathol. 2000; 156:
1773–9.
127. Wheeler JM, Loukola A, Aaltonen LA, 
et al. The role of hypermethylation of the
hMLH1 promoter region in HNPCC versus
MSI sporadic colorectal cancers. J Med
Genet. 2000; 37: 588–92.
128. Potocnik U, Glavac D, Golouh R, et al.
Causes of microsatellite instability in col-
orectal tumors: implications for hereditary
non-polyposis colorectal cancer screen-
ing. Cancer Genet Cytogenet. 2001; 126:
85–96.
129. Ollikainen M, Hannelius U, Lindgren CM,
et al. Mechanisms of inactivation of MLH1
in hereditary nonpolyposis colorectal car-
cinoma: a novel approach. Oncogene.
2007; 26: 4541–9.
130. Ramsoekh D, van Leerdam ME, Wagner
A, et al. Review article: detection and man-
agement of hereditary non-polyposis col-
orectal cancer (Lynch syndrome). Aliment
Pharmacol Ther. 2007; 26: 101–11.
131. Ferreira AM, Westers H, Wu Y, et al. Do
microsatellite instability profiles really dif-
fer between colorectal and endometrial
tumors? Genes Chromosomes Cancer.
2009; 48: 552–7.
132. de Leeuw WJ, Dierssen J, Vasen HF, 
et al. Prediction of a mismatch repair gene
defect by microsatellite instability and
immunohistochemical analysis in endome-
trial tumours from HNPCC patients. 
J Pathol. 2000; 192: 328–35.
133. Hewitt MJ, Wood N, Quinton ND, et al.
The detection of microsatellite instability in
blind endometrial samples–a potential
novel screening tool for endometrial
 cancer in women from hereditary
 nonpolyposis colorectal cancer families?
Int J Gynecol Cancer. 2006; 16: 1393–400.
